stockportfolio.pro
Stocks / GYRE vs TRAX
GYRE vs TRAX
Gyre Therapeutics, Inc. and First Tracks Biotherapeutics, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| Gyre Therapeutics, Inc. (GYRE) | First Tracks Biotherapeutics, Inc. (TRAX) | |
|---|---|---|
| Market cap | $0.6B | $0.6B |
| Revenue (latest FY) | $116.59M | $0 |
| Net income (latest FY) | $5.03M | $-163.71M |
| Revenue growth (5y CAGR) | 41.0% | — |
| Net margin | 4.3% | — |
| Return on equity | 4.7% | -41.8% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 3 | 0 |
| Positive free cash flow | No | No |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open GYRE — free Open TRAX — freeFrequently asked questions
Which is bigger, GYRE or TRAX?
Gyre Therapeutics, Inc. is larger by market capitalization — $0.6B versus $0.6B.
Which grows faster, GYRE or TRAX?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.